950769-61-6

Basic information

• Product Name: 7-[2-(Morpholin-4-yl)ethoxy]-2-(4-aminophenyl)imidazo[2,1-b][1,3]benzothiazole
• Synonyms: 7-[2-(Morpholin-4-yl)ethoxy]-2-(4-aminophenyl)imidazo[2,1-b][1,3]benzothiazole;2-(4-aMinophenyl)-7-(2-Morpholin-4-ylethoxy)iMidazo[2,1-b][1,3]benzothiazole, 7-(2-Morpholin-4-yl-ethoxy)-2-(4-aMino-phenyl)iMidazo[2,1-b][1,3]benzothiazole;4-[6-(2-morpholinoethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]aniline;Benzenamine, 4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]-
• CAS NO: 950769-61-6
• Molecular Formula: C₂₁H₂₂N₄O₂S
• Molecular Weight: 394.48998
• Mol File: 950769-61-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 597.414°C at 760 mmHg
• Flash Point: 315.105°C
• Appearance: /
• Density: 1.417g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.72
• CAS DataBase Reference: 7-[2-(Morpholin-4-yl)ethoxy]-2-(4-aminophenyl)imidazo[2,1-b][1,3]benzothiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 7-[2-(Morpholin-4-yl)ethoxy]-2-(4-aminophenyl)imidazo[2,1-b][1,3]benzothiazole(950769-61-6)
• EPA Substance Registry System: 7-[2-(Morpholin-4-yl)ethoxy]-2-(4-aminophenyl)imidazo[2,1-b][1,3]benzothiazole(950769-61-6)

Safety Data

• Hazardous Substances Data: 950769-61-6(Hazardous Substances Data)

Usage

General Description

The chemical 7-[2-(Morpholin-4-yl)ethoxy]-2-(4-aminophenyl)imidazo[2,1-b][1,3]benzothiazole is a compound with potential pharmaceutical applications. It contains a morpholine ring, an ethoxy group, an aminophenyl group, and an imidazo-benzothiazole core structure. 7-[2-(Morpholin-4-yl)ethoxy]-2-(4-aminophenyl)imidazo[2,1-b][1,3]benzothiazole has been studied for its potential as an anticancer agent, as it has shown promising activity in inhibiting the growth of cancer cells. Additionally, the morpholine and ethoxy groups in this compound may contribute to its ability to penetrate cell membranes and reach its target within the body. Further research is ongoing to fully understand the potential therapeutic applications of this compound.

InChI:InChI=1/C21H22N4O2S/c22-16-3-1-15(2-4-16)18-14-25-19-6-5-17(13-20(19)28-21(25)23-18)27-12-9-24-7-10-26-11-8-24/h1-6,13-14H,7-12,22H2

Upstream product

• 950769-60-5 4-(2-((2-(4-nitrophenyl)benzo[d]imidazo[2,1-b]thiazol-7-yl)oxy)ethyl)morpholine 
• 99-81-0 4-Nitrophenacyl bromide 
• 26278-79-5 2-amino-6-hydroxybenzothiazole 
• 914224-34-3 2-(4-nitrophenyl)imidazo[2,1-b][1,3]benzothiazol-7-ol 
• 1747-60-0 6-methoxybenzothiazol-2-ylamine 
• 100-02-7 4-nitro-phenol 
• 65300-53-0 4-[2-(4-nitrophenoxy)ethyl]morpholine 
• 52481-41-1 4-(2-morpholinoethoxy)aniline 

Downstream Products

• 950769-58-1 quizartinib 
• 1225542-12-0 AC₈₈₆ 
• 1225542-13-1 1-(5-(2-hydroxy-1-hydroxymethyl-1-methylethyl)isoxazol-3-yl)-3-(4-(7-(2-morpholin-4-ylethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea 
• 1225542-14-2 1-(5-(2-hydroxy-1,1-bis(hydroxymethyl)ethyl)isoxazol-3-yl)-3-(4-(7-(2-morpholin-4-ylethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea 
• 1300733-71-4 N-(3-(2-fluoropropan-2-yl)isoxazol-5-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea 
• 1300734-21-7 N-(5-(tert-butyl-D₉)isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea 

Relevant articles and documents

Synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors

As a class III receptor tyrosine kinase (RTK), FMS-like tyrosine kinase 3 (FLT3) is always overexpressed in many cases of acute leukemia. This paper studies the structure-based synthesis and biological evaluation of diaryl urea derivatives as FLT3 inhibitors. Encouragingly, compounds 15b, 16b, 24a, and 24c showed excellent biological activities in a low nanomolar range. In particular, compound 16b demonstrated significant inhibitory potency against FLT3-ITD (IC50 = 5.60 nM) and better antiproliferative activity than quizartinib against MV4-11 cell line (IC50 = 0.176 nM). It is indicated that compound 16b for the treatment of acute myeloid leukemia could be very promising.

PROCESS FOR THE PREPARATION OF IMIDAZO[2,1-B][1,3]BENZOTHIAZOLE DERIVATIVES

Provided herein are process for the preparation of N-(5-ferf-butyl-isoxazol-3-yl)- N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-fe][l,3]benzothiazol-2-yl]phenyl}urea, or a pharmaceutically acceptable salt, solvate, hydrate, or polymorph thereof. N-(5-tert- Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,l-and][l,3]benzo- thiazol-2-yl]phenyl}urea is useful for treating, preventing, and/or managing diseases or conditions, including but not limited to, proliferative diseases, FLT-3 mediated diseases, and cancers. N-(5-ferf-Butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl- ethoxy)imidazo[2,l-and][l,3]benzothiazol-2-yl]phenyl}urea is represented by the structure:

IMIDAZOLOTHIAZOLE COMPOUNDS AS MODULATORS OF PROTEIN KINASE

Compounds, compositions and methods are provided for modulating the activity of receptor kinases and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder mediated by receptor kinases.